

Tocilizumab is more effective than adalimumab at reducing signs and symptoms of rheumatoid arthritis

6 June 2012

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p

APA citation: Tocilizumab is more effective than adalimumab at reducing signs and symptoms of rheumatoid arthritis (2012, June 6) retrieved 13 June 2021 from <https://medicalxpress.com/news/2012-06-tocilizumab-effective-adalimumab-symptoms-rheumatoid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.